Pregabalin for neuropathic pain in primary care settings: recommendations for dosing and titration
Open Access
- 2 January 2021
- journal article
- review article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 133 (1) , 1-9
Abstract
Pregabalin is one of the first-line treatments approved for the management of neuropathic pain (NeP). While many patients benefit from treatment with pregabalin, they are often treated with suboptimal doses, possibly due to unfamiliarity around prescribing the drug and/or side effects that can occur with up-titration. This narrative review discusses key aspects of initiating, titrating, and managing patients prescribed pregabalin therapy, and addresses concerns around driving and the potential for abuse, as well as when to seek specialist opinion. To ensure that patients derive maximum therapeutic benefit from the drug, we suggest a ‘low and slow’ dosing approach to limit common side effects and optimize tolerability alongside patients’ expectations. When requiring titration to higher doses, we recommend initiating ‘asymmetric dosing,’ with the larger dose in the evening. Fully engaging patients in order for them to understand the expected timeline for efficacy and side effects (including their resolution), can also help determine the optimal titration tempo for each individual patient. The ‘low and slow’ approach also recognizes that patients with NeP are heterogeneous in terms of their optimal therapeutic dose of pregabalin. Hence, it is recommended that general practitioners closely monitor patients and up-titrate according to pain relief and side effects to limit suboptimal dosing or premature discontinuation.Keywords
This publication has 74 references indexed in Scilit:
- Neuropathic pain in the community: More under-treated than refractory?Pain, 2013
- Pain Alleviation and Patient-Reported Health Outcomes following Switching to Pregabalin in Individuals with Gabapentin-Refractory Neuropathic Pain in Routine Medical PracticeClinical Drug Investigation, 2012
- Clinical characteristics and patterns of healthcare utilization in patients with painful neuropathic disorders in UK general practice: a retrospective cohort studyBMC Neurology, 2012
- Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteersPharmacology Biochemistry and Behavior, 2012
- The cognitive impact of antiepileptic drugsTherapeutic Advances in Neurological Disorders, 2011
- Effects of Benzodiazepines, Antidepressants and Opioids on DrivingDrug Safety, 2011
- NeuPSIG guidelines on neuropathic pain assessmentPain, 2011
- Drug-Related Sleep Stage Changes: Functional Significance and Clinical RelevanceSleep Medicine Clinics, 2010
- A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and GabapentinClinical Pharmacokinetics, 2010
- painDETECT: a new screening questionnaire to identify neuropathic components in patients with back painCurrent Medical Research and Opinion, 2006